| Document Date: 2014-05-27 19:03:05 Open Document File Size: 4,36 MBShare Result on Facebook
Company BT / HCV / SPRINT / BOC / EPO / / Continent North America / Europe / / Country Belgium / United States / Canada / Scotland / / Event FDA Phase / / / IndustryTerm HCV therapy / unsafe medical tools / blood products / treatment algorithms / food / HCV treatment / treatment of patients with advanced liver disease / healthcare providers / therapy for HCV / healthcare burden / / MedicalCondition SCAR / HIV / viral infection / HBV / recovered infection / cirrhosis / hepatitis C / hepatitis B / chronic stage / obesity / acute and chronic HCV / liver cirrhosis / severe liver disease / chronic cases / liver disease / Introduction Hepatitis C / infections / alcoholism / cirrhosis ranges / Acute hepatitis C / untreated HIV infection / insulin resistance / disease / hepatocellular carcinoma / chronic liver disease / liver diseases / chronic / acute hepatitis / slow HCV disease / chronic alcohol consumption / diabetes / relapsers ºfibrosis / advanced liver injury / diseases / acute and chronic hepatitis C / suspected acute hepatitis C / epilepsy / infection / transfusion-associated hepatitis C. Similarly / chronic hepatitis / chronic infection / depression / extrahepatic diseases / cryoglobulinemia / Chronic hepatitis C / hemochromatosis / syndrome / disorders / Fibrosis / / MedicalTreatment blood transfusion / liver transplant / acupuncture / antiviral therapy / contraception / immunosuppression / / Organization European Association for the Study of the Liver / EASL CPGs / EASL Governing Board / European Union / / Person Helmut Diepolder / Markus Peck / Antonio Craxi / Francesco Negro / David Mutimer / Stephen Ryder / Stefan Zeuzem / Michael Fried / / / Position physician / Professor / Coordinator / / Product CPGs / ribavirin / HCV / A1 / / Region Western Europe / Mediterranean / Central Africa / / Technology Management algorithms / antibodies / transplantation / genotyping / treatment algorithms / genotype / /
SocialTag |